

Date: June 12, 2025

The Board of Directors,
Aakaar Medical Technologies Limited
801, Heritage Plaza,
Telli Galli Cross Road, Andheri (East),
Mumbai-400069 Maharashtra, India

Dear Sir,

Re: Proposed initial public offering of equity shares of face value of Rs. 10/- each (the "Equity Shares") of Aakaar Medical Technologies Limited (the "Company") (the "Issue" or "IPO")
Sub: Promoter Group Entities – Confirmations

We hereby give our consent to include our name in the Red Herring Prospectus and the Prospectus as member of Promoter Group.

We, in our capacity as a part of the promoter group (as defined in Regulation 2(1)(pp) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 of the Company, hereby declare that the following representations are accurate and complete, and that we have verified the same appropriately

1. We are a promoter group member of the Company under Regulation 2(1)(pp)(iv)(A) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 in as much as we are a sole proprietor, we state that Dilip Meswani Promoter of the Company is the Sole Proprietary of Coherent Medical system.
2. Except as disclosed below, we do not hold any equity shares in any entities, as per the following thresholds:

Nature of Relationship	Entity
Any body corporate in which 20% or more of the equity share capital is held by the Promoter or an immediate relative of the Promoter or a firm or Hindu Undivided Family in which the Promoter or any one or more of his immediate relative is a member	NIL
Any body corporate in which a body corporate as mentioned above holds 20% or more, of the equity share capital	NIL
Any HUF or firm in which the aggregate shareholding of the promoter and his immediate relatives is equal to or more than 20% share of the total capital	NIL

3. Except as disclosed below, we do not hold any equity shares, warrants/convertible securities, or any employee stock options in the Company:

Number of equity shares	Number and details of outstanding warrants/convertible instruments
NA	NIL

4. We consent to lock-in our entire pre-IPO equity share holding, if required as per provisions of SEBI ICDR Regulations, for such other time, and in the manner as is or may be prescribed under the SEBI ICDR Regulations for the IPO.
5. We confirm that, as on date, no compliance is required to be made by us under the provisions of Companies (Significant Beneficial Ownership) Rules, 2018 (“SBO Rules”), and that we undertake to comply with the SBO Rules, as necessary, and to the extent applicable to us, upon further notification by the MCA, within the timelines as may be specified under the applicable SBO Rules.
6. We have no interest in the Company or any of its joint ventures, subsidiaries and associates except to the extent of NIL Equity Shares held by us, and to the extent of the benefits arising out of such shareholding and except the following:
7. We have not, directly or indirectly, financed, sold or purchased any securities of the Company during the six month period preceding the date of filing the IPO related issue document with NSE Emerge, (“NSE”), except:

Date of Transfer / Transmission	Nature of transaction	No. of Equity Shares	Face Value per Equity Share (in ₹)	Issue Price / Acquisition Price / Transfer price per Equity Share (in ₹)
NIL	NIL	NIL	NIL	NIL

8. We undertake that transactions in equity shares of the Company (“**Equity Shares**”), by us during the period between the date of filing the Draft Red Herring Prospectus with NSE Emerge and the date of commencement of trading of the Equity Shares, would be reported to (a) the Company, (b) the stock exchange (in which the securities of the Company are listed) and, (c) the Book Running Lead Manager to the IPO, within 24 hours of the relevant transaction.
9. None of companies in which we were or are, (i) a promoter, or (ii) a person in control, is prohibited or debarred from accessing or operating in the capital markets under any order or directions made by the SEBI, and no penalty has been imposed on such companies in the last 5 financial year including any outstanding action by any statutory or regulatory authority in India or abroad.
10. None of companies in which we were or are, (i) a promoter, or (ii) a person in control, has committed any violation/s of securities law/s, nor have there been any adverse proceedings or findings against such companies, past or pending, as regards to compliance with securities law/s;
11. We have not, at any stage, been prohibited or debarred from accessing the capital markets or from buying, selling or dealing in securities under any order or direction passed by SEBI or any securities market regulator in any other jurisdiction or any other authority/court and no penalty has been imposed on us in the last 5 financial year including any outstanding action by any statutory or regulatory authority in India or abroad.
12. We are not and were not associated with the securities related business in any manner nor were/are we registered with the SEBI.
13. We are not/ were not associated or registered with Insurance Regulatory and Development Authority (“IRDA”) or Reserve Bank of India (“RBI”) or Pension Fund Regulatory and Development Authority (“PFRDA”) or none of proprietorship firm(s) or partnership firm(s) or Hindu Undivided Family(ies) or limited liability partnership(s) belonging to us or body corporate of which we are member or director are or were associated or registered with IRDA or RBI or PFRDA.
14. We are not and were not associated with the securities market in any manner, nor were/are we associated with any firms/concerns that are or were/are registered with the SEBI, except as follows:

Sr. No	Details	Particulars
1.	Name of the entity	NIL
2.	Details of association with the said entity	NIL
3.	Registration Number	NIL
4.	If registration has expired, reasons for non-renewal	NIL
5.	Details of any enquiry/investigation conducted by SEBI at any time	NIL
6.	Disciplinary Action including penalty imposed by SEBI or stock exchanges against the promoters in the last five financial years including outstanding action (penalty includes deficiency/warning letter, adjudication proceedings, suspension/cancellation / prohibitory orders)	NIL
7.	Outstanding fees payable to SEBI by the entity, if any	NIL

15. Further, we confirm that:

i. We have done purchase (as below) within the two preceding years.

Date	Transaction	Amount
31.03.2024	Sale of Spare part to Aakaar Medical Technologies Pvt Ltd.	176,364.00

- ii. We have no interest in the appointment of any intermediaries to the IPO, including the Book Running Lead Manager, the underwriters, the registrars or the bankers to the IPO;
- iii. We have not entered, and shall not enter, into any buy-back and/or standby arrangements, directly or indirectly, for purchase of any of the Equity Shares to be issued and sold in the IPO from any person;
- iv. neither us nor any person related to us shall participate in the IPO and/or apply under the anchor investor portion of the IPO;
- v. We have no intention to subscribe to the securities issued pursuant to the proposed IPO;
- vi. We have not agreed to make, and agree not to make, any payment, directly or indirectly, in the nature of discounts, commission allowance or otherwise to any persons who receive allotments in the IPO;
- vii. We have not been prohibited or debarred from accessing capital markets or from buying, selling or dealing in securities under any order or direction passed by the SEBI or any securities market regulator in any other jurisdiction or any other authority/court;
- viii. We have not been classified or identified as a wilful defaulter or fraudulent borrower by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters and fraudulent borrowers issued by the Reserve Bank of India or any other statutory or regulatory authority; Our name has not appeared in the past and is not presently appearing in the Wilful Defaulters List as per the most recently updated database of the Credit Information Bureau (India) Limited, "CIBIL Website" or other authorities either in the past or present;
- ix. We have not been classified as a fugitive economic offender as defined under Section 12 of the Fugitive Economic Offenders Act, 2018.
- x. We have not purchased, sold or financed, directly or indirectly the purchase of securities of the Company and its subsidiaries during the last six months.
- xi. We have not, at any point in time, committed or been found to have committed, any violation/s of any securities law/s, nor are any allegations pending against us in this regard before any court, tribunal or other forum,
- xii. We have not been subject to any adverse findings against us in connection with compliance with securities law/s;
- xiii. We have not, during the preceding six months, entered into any financing arrangements whereby we have financed the purchase by any other person/entity of securities of the Company, other than in the normal course of the business of the financing entity;
- xiv. No notice or action has been issued or initiated against us, with respect to our association with any entities,

- in any capacity; and
- xv. [Except as stated below] there is no litigation or proceeding, threatened or pending, against us or any of the companies in which we are interested as a promoter, which could have a materially adverse effect on the position of the Company.

16. Except as stated below, we have not engaged in the sale or purchase of securities of the Company within three years of filing the DRHP with NSE Emerge/filing of the RHP with the RoC which in aggregate is equal to or greater than 1% of the pre-issue capital of the Company:

Transaction	Date	No. of securities <i>[Please state whether Equity Shares or any other type of security]</i>
NIL	NIL	NIL

17. None of the Equity Shares held or owned (beneficially or otherwise) by us are pledged or otherwise encumbered, including subject to any non-disposal undertaking including with any bank or financial institution and/or with any other creditor as security for loans granted by such banks, financial institutions or any other creditor or otherwise.
18. No incentive or payment, whether direct or indirect, in any manner, whether in cash or kind or services or discount or commission allowance or otherwise shall be provided by me/us to any person for making an application for Equity Shares in the Issue or to any person who receive allotments in the Issue, except for fees or commission for services rendered in relation to the Issue.
19. There is no proposal whereby we will receive any portion of the proceeds from the proposed IPO and there is no material existing or anticipated transaction with us in relation to the utilization of such proceeds. Further, there is no arrangement between the Company and us pursuant to which the proceeds of the IPO shall be indirectly routed to us.
20. My/ our entire shareholding in the Company [shall be in dematerialized form prior to filing the RHP with the RoC]/[is in dematerialized form as of the date of this certificate] A copy of the latest shareholding statement from the depository participant is annexed herewith as Annexure
21. We further confirm that we have not issued equity shares in the past to more than 49 persons/200 persons as applicable in violation of:
- Section 67(3) of the Companies Act, 1956, as amended; or
 - Relevant Section(s) of Companies Act, 2013, including Section 42, as amended and the rules notified thereunder;
 - The SEBI regulations including the SEBI (Disclosure and Investor Protection) Guidelines, 2000, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2009, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, each as amended, as applicable.
22. I/We have not been in default in payment of listing fees to any stock exchange in the last three years or have not been delisted or suspended in the past and have not been proceed against by SEBI or other regulatory authority for any reason.

We confirm that any changes to the above will immediately be intimated to the Company and the Book Running Lead Manager to the IPO, till the date on which the securities of the Company to be issued pursuant to the IPO,

start trading on the stock exchange/s. In the absence of any such communication, the above information should be taken as updated information till the date of listing of equity shares issued pursuant to the IPO.

This certificate may be relied upon by the Book Running Lead Manager and the Legal Advisor in relation to the IPO. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the IPO related issue documents.

I/We hereby indemnify and agree to keep indemnified, saved, defended and harmless the Book Running Lead Manager and Legal Advisor to the proposed IPO of the Company and all persons claiming under them ("Indemnified Persons"), from and against all losses and/or damages arising as a result of the aforementioned representations made by me/us in order to disclose details of the same in the Issue Documents including the Draft Red Herring Prospectus, the Red Herring Prospectus, the Prospectus, the Abridged Prospectus and any other addendum thereto (together referred as "Offer Documents"), for the Issue or arising as a result of any notices, proceedings, litigations, claims, penalties, demands and costs that may be made and/or raised on the Indemnified Persons by any concerned authority(ies) and/or with regard to any matter arising in connection thereto or otherwise by reason of the matter contemplated herein and/or sustained by the Book Running Lead Manager and/or Legal Advisor to the Issue as a result of any statements, representations, assurances, confirmations hereinunder given being untrue.

Yours sincerely,
For Coherent Medical Systems



Name of Proprietor: Dilip Meswani
Designation: Proprietor

Cc:

The Book Running Lead Manager ("BRLM")

Indorient Financial Services Limited
501, Executive Spaces, Rustomjee Central Park,
A-wing, Andheri Kurla Road, Chakala,
Mumbai – 400093, Maharashtra, India

Legal Advisors to the Issue

Vidhigya Associates
501, 5th floor, Jeevan Sahakar Building
Homji Street, Fort, Mumbai 400001,
Contact Person: Rahul Pandey
Email: rahul@vidhigyaassociates.com
Mobile: +91 8424030160

